METHOD FOR PREDICTING THE RESPONSE TO TREATMENT BY TYROSINE KINASE INHIBITORS TARGETING THE BCR-ABL FUSION PROTEIN IN CHRONIC MYELOID LEUKAEMIA PATIENTS

摘要

The present invention relates to a method for determining if an individual suffering from chronic myeloid leukemia (CML) is at risk of developing resistance to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein or if the individual is likely to respond to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein, comprising: a) determining the expression level of at least one of the genes selected from the group consisting of : RAD51 -like 1 (S. cerevisiae), Aurora kinase B, and Phosphatase and tensin homolog (mutated in multiple advanced cancers 1); in cells of the individual suffering from CML; b) comparing the determined expression level for each gene respectively to a predetermined reference expression level; c) deducing therefrom if the individual suffering from CML is at risk of developing resistance to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein or if the individual is likely to respond to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein.